Pharmicell Co., Ltd.
Pharmicell is a KOSPI-listed (005690) company based in Seoul. Its stem-cell therapy Hearticellgram-AMI, for acute myocardial infarction, has been approved in South Korea since 2011.
| Headquarters | Seoul, South Korea |
|---|---|
| Listing | KOSPI:005690 |
| Lead asset / stage | Hearticellgram-AMI Approved — South Korea |
| Latest event | Pharmicell announced sponsorship of the Cha Hong-do Medical Award. |